DNLI · Denali Therapeutics Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Denali reported a strong first full commercial quarter for Ablea with $3.6M in net product revenue and guided Q3 revenue to $10–12M, while advancing two Alzheimer's programs into the clinic and strengthening its balance sheet to over $1.1B in pro forma cash following a $195M priority review voucher sale; the company also pushed out DNL593 data to 2027.
- + Ablea generated $3.6M in net product revenue in its first full commercial quarter, ahead of internal expectations.
- + Company guided Q3 2026 Ablea net product revenue to $10.0–12.0 million.
- + Pro forma cash strengthened to over $1.1B after $195M July PRV sale proceeds, adding strategic flexibility.
- + DNL593 received FDA Orphan Drug Designation for FTD-GRN.
- − DNL593 (FTD-GRN) data timing pushed from end of 2026 to 2027 to allow longer observation of biomarkers including NfL.
- − Net loss widened to $127.6M in Q2 2026 from $124.1M in Q2 2025, with SG&A up on Ablea launch investment.
- − Partnered DNL151 (LRRK2) failed the global Phase 2b LUMA study in early-stage Parkinson's, ending development in idiopathic PD.
- − Takeda terminated the DNL593 collaboration, returning full program rights to Denali.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DNLI
this stock
Denali Therapeutics Inc.
|
$3.25B | +16.1% | — | — | 10.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.5% | +46.2% | 30.7 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DNLI | -7.3% | -11.2% | -7.5% | -7.3% | +16.1% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -9.2% | -13.1% | -18.3% | -9.2% | +2.1% |